Diabetes Trials Unit
Tel: 01865 857240
Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.
Benchmarking the Cost- Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data
Jose Leal et al.
Diabetes Care 2020
Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
Laurie L. Baggio et al.
Nat Commun. 2020;11:3766
Predicting Post One-year Durability of Glucose-lowering Monotherapies in Patients with Newly-diagnosed Type 2 Diabetes Mellitus - A MASTERMIND Precision Medicine Approach (UKPDS 87)
Olorunsola F. Agbaje et al.
Diabetes Research and Clinical Practice 2020
Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial
Hertzel C. Gerstein et al.
Diabetes Care 2020
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial
Finlay A McAlister et al.
Eur J Heart Fail. 2020
Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA-REG OUTCOME Trial be Explained by the Changes Seen in Conventional Cardiovascular Risk Factor Levels?
Ruth L. Coleman et al.
Diabetes Obes Metab. 2020;22:1151-1156